Nonetheless, anti-PD-1 therapy achieves potent antiglioma activity in mouse glioma activity possibly through the depletion of PD-1+ macrophages and proinflammatory polarization in the glioblastoma microenvironment (51). The gene discussed is PDCD1; the disease is central nervous system cancer.